The success of Viagra initially fueled a boom for pharma, nevertheless recent developments present a murky picture for shareholders. Off-patent competitors are eating into revenue, and continued patent challenges add further risk to the situation. While specific companies could still benefit from related services, the broader direction suggests … Read More